Molecular regulation of TNFa production 2.4. Effects of TNFa on cardiac function
The TNFa gene is one of the earliest genes to be Administration of large amounts of TNFa to the circulatranscribed after T lymphocyte activation. Transcription of tion causes shock due to a decrease in peripheral vascular mRNA does not require de novo protein synthesis, as do resistance and direct cardiac effects [33] . Mann has argued other cytokines, such as IL-2 [12] . There is a high baseline that the net effect of TNFa on cardiac function will depend transcription of TNFa mRNA by comparison to other on the amount and duration of TNFa expression. Short cytokines such as TNFb [13] .
term expression of TNFa within the heart may be an Both positive and negative regulatory gene elements adaptive response to 'stress', whereas long term expression affect TNFa gene transcription [14] , as well as other may be maladaptive by producing cardiac decompensation cytokines, such as GM-CSF and IL-4. These can differen- [34] . Excessive TNFa levels can produce left ventricular tially regulate transcription, through acting on upstream dysfunction [35] , cardiomyopathy, and the clinical manipromoter elements [15] .
festation of heart failure [36, 37] . TNFa can affect heart Production of the TNFa gene product is regulated at the failure, in part, by stimulating myocyte hypertrophy, post-transcriptional level. The TNFa mRNA has a very through the generation of reactive oxygen intermediates in short half-life (30 min) by comparison to the mRNA cardiac myocytes [38] , and also by inducing ventricular half-life of TNFb (5.5 h) [13] . A conserved consensus remodeling, through stimulating extracellular matrix prosequence (UUAUUUAU) in the 39 untranslated region of tein production and increased turnover of matrix [35, 39] . the mRNA destabilizes the mRNA and shortens its halfTNFa will cause cardiomyocyte loss, through necrosis, or life [16, 17] . Various degradative pathways can degrade apoptosis, as demonstrated in in vitro models. It can induce mRNA [18] , for example, via poly A tail removal [19] .
apoptosis directly, via the TNF receptor, or indirectly, These regulatory mechanisms limit the use of in situ through stimulation of nitric oxide (NO) production [40] . hybridisation techniques in detecting mRNA transcripts.
Evidence now suggests that cardiotropin-1, produced by Messenger RNA's sensitivity to tissue fixation, can further cardiomyocytes, is able to inhibit cytokine-induced carresult in false negative results. TNFa production is also diomyocyte apoptosis in vitro [40] . The effects of TNFa subjected to translational control. Translational derepreson myocardial contractility and left ventricular dysfuncsion, occurs following lipopolysaccharide (LPS) induction tion, were first demonstrated in animal models [41, 42] . and the translational rates of TNFa mRNA are accelerated TNFa can depress myocardial function through two [18, 20] . TNFa mRNA expression is not constitutive in major pathways. The NO-dependent pathway [35, 36, 43] , adult myocardium, but induced [10, 21] . However, constituand the sphingomyelinase (sphingosine-dependent) pathtive expression has been documented in other normal way [44] . Activation of the NO-dependent pathway can tissues, such as the spleen, liver, and kidney [21, 22] .
induce negative inotropic effects on isolated cardiac myocytes, causing immediate cell contraction, through 2.3. Genetic variation in TNFa levels stimulation of iNOS production [45] . The resultant increase in NO will act as an important intracellular sigWithin the normal population, there is considerable nalling molecule, that mediates the negative inotropic variation in the amount of TNFa produced. Such variation effects. Even though TNF has negative inotropic effects on is also seen when peripheral blood lymphocytes [23] and isolated myocytes, its net effect on the whole heart is an mononuclear cell populations [24] are stimulated with increase in end diastolic pressure, resulting in increased endotoxin [25, 26] . Polymorphisms within microsatellite ventricular volume. The induction of iNOS and its effects regions flanking the TNF locus have been identified on cardiac function in allograft rejection, have been [27, 28] . Five microsatellite regions are described: TNF a, reviewed in detail [46] . b, c, d and TNF-e. High levels of in vitro TNFa production Activation of the sphingomyelinase pathway will result from mononuclear cell populations are associated with the in breakdown of the phospholipid, sphingomyelin, to its TNFa2 allele and low levels with TNFa6 allele, respectivemetabolites ceramide and sphingosine [47] . Both can act as ly. In addition, there are polymorphisms within the TNFa second messengers in the signalling pathways. Edmunds promoter region as follows: a point mutation of G to A in and Woodward showed that the early increase in coronary position -308 (termed TNF1 and TNF2, respectively) and perfusion pressure following TNFa treatment of rat perin position -238 predisposes to higher TNF production.
fused hearts, was due to early coronary vasoconstriction, Studies using reporter gene assays have demonstrated an mediated by sphingosine and thromboxane A2 [44] . increase in the level of TNF gene transcription when the TNFa, at low non-toxic concentrations, depresses cul-TNF2 allele is inserted [29] [30] . Two additional G /A tured myocyte contractile performance independently of mutations at position -376 and -163 are described [31] . An NO, through blocking a-and b-adrenoceptor-stimulated insertional 'C' polymorphism is also described at position increase in contractility [35, 48] . Several other studies have 170 [32] resulting in an 8'C' rather than 7'C' repeated analysed the effects of TNFa on myocardial calcium sequence.
handling as one mechanism of TNFa-induced contractile dysfunction [49] . TNFa-induced disruption of calcium standard for monitoring cardiac transplants. Rejection is handling may lead to dysfunctional excitation-contraction graded histologically from mild to severe, depending on coupling causing systolic and / or diastolic dysfunction the extent and type of cellular infiltrate and degree of [37] . The observations of Schreiner suggest that the effects myocyte damage, according to the Working Formulation of of TNFa on cardiac contractile cell function, are reversthe International Heart and Lung Transplant Study Group ible, both in animal models, and in clinical manifestations (ISHLT) [51] . The immunosuppressive regimen following of heart failure, including allograft rejection [35] . The transplantation is altered according to the grade of rejecactions of TNFa on left ventricular dysfunction were tion and clinical symptoms. However, due to limitations of shown to be partially reversible in animal models followthe biopsy procedure (such as sampling error), the risk of ing treatment with TNFa anatgonists [50] . The effects of over-immunosuppression or under-immunosuppression reTNFa are listed in Table 1 . mains a problem, particularly for the management of mild to focal moderate rejection (ISHLT grades 1 and 2, respectively) [53] [54] [55] . Hence there is a pressing need to 3. Role of TNFa in allograft rejection identify a marker that can predict rejection. An alternative non-invasive method of diagnosis, such as serum analysis, 3.1. Allograft rejection: the need for a predictor would be of great benefit.
Acute cardiac allograft rejection is an immune-mediated 3.2. Involvement of TNFa in rejection response, hallmarked by cellular infiltration and myocyte damage in the transplanted heart. The infiltrate consists TNFa has many proinflammatory functions and hence largely of T lymphocytes and macrophages. In more severe has been implicated in the initiation and orchestration of forms, polymorphonuclear cells and eosinophils are also the rejection response. The rejection response is initiated recruited [51] . Both the CD41 T lymphocytes and macroby activation of CD41 T helper cells by alloantigen, either phages play a major role in directing the rejection rethrough direct stimulation by donor antigen presenting sponse, through elaboration of initiator cytokines, such as cells, or indirectly by recipient antigen presenting cells. TNFa, and the induction of effector molecules such as NO Activated T helper cells will release initiator cytokines [52] . Moderate to severe rejection episodes may initially such as IL-1b, IL-2, and interferon g, which in turn be asymptomatic in some cases, but are often followed by activate macrophages to release TNFa [56] . TNFa particibreathlessness, pyrexia, and raised intracardiac pressures pates in initiating the response through upregulation of (end-diastolic). Lesser grades of rejection have no clinical MHC molecule expression required for specific T cell signs or symptoms. In the early 1970s, endomyocardial activation and increased cellular infiltration through endobiopsy (EMB) was introduced, and is now the 'gold ' thelial cell activation and adhesion molecule expression [57] . TNFa will further maintain the inflammatory rethe major disadvantage of the EMB technique [77, 78] , sponse within the rejection infiltrate through upregulation calculated at 2% if four samples are taken, and 5% if only of adhesion molecules, increased vascular permeability, three samples are taken [79] . and activation of inflammatory cells [57] (Table 1) .
Subject variation in serum TNFa levels have led to Early suggestions that TNFa may play a role in the studies on the genetic control of TNFa production [80-rejection response, came from two sources. Firstly, ob-81]. Turner et al. (1995) , studied the relationship between servations were made that cardiac [58] , renal [59, 60] , and TNFa gene polymorphisms and TNFa production in liver [61] , transplant recipients, had raised serum levels of immunosuppressed heart transplant recipients. Endotoxin TNFa following rejection episodes, although no causal stimulation of whole blood samples demonstrated a signifirelationship was established. The second source of evicant association between the microsatellite allele TNFd3 dence came from animal models of acute cardiac allograft with TNF production [80] . When TNFa gene polymorrejection. Anti-TNF antibody therapy prolonged cardiac phisms are studied in relation to those of interleukin-10 allograft survival in the rat [62, 63] , although this was not (IL-10), (an immunosuppressive cytokine that down-regdemonstrated for allogenic skin in Rhesus monkeys [64] .
ulates the expression of TNFa [81] ), certain combinations In addition, localization of the protein and mRNA tranof TNF-A and IL-10 promoter gene polymorphisms are scripts within the rejection infiltrate of both cardiac [5, 65] , associated with acute cardiac rejection. In patients with and renal [66, 67] allografts, provided supporting evidence high levels of rejection, significantly more patients were for the role of TNFa in rejection. In cardiac allografts, the typed as high TNFa / low IL-10 producers compared with presence of protein TNFa correlated with higher grades of patients of low rejection levels [81] . In addition, we have rejection [5] . When EMB were examined for both TNF identified a subgroup of heart transplant recipients who mRNA transcript and protein product expression, using suffered acute cellular rejection that did not resolve with combined in situ hybridisation and immunohistochemistry immunosuppressive therapy and ultimately led to their [65] , approximately half of the cases positive for TNF death. TNFa genotyping of these cases has identified a mRNA transcript were also positive for protein product.
significant increase in the frequency of the TNF2 alleles by Although there was no correlation between expression and comparison to the whole population of heart transplant grade of rejection, there was a trend to an increased recipients. More than 82% of acute rejectors had the TNF2 number of positive cells in samples taken early after allele, by comparison to only 35% in the whole transplant transplantation.
population (P,0.01) [Azzawi, unpublished observations]. Analysis of serum TNFa levels have shown that in most Although these genetic studies represent investigations into cases with elevated levels, the amount of TNFa in samples a few out of many different alleles for TNFa and its taken within the first 30 days post-transplantation did not promoters, they provide early, but promising, findings. relate to grade of rejection [65] . In another study, serum levels were significantly increased in patients with moder-3.3. Can TNFa be used as a predictor for rejection? ate to severe rejection (P50.001) for samples taken in the first week post-transplantation [68]. Jordan et al. showed
We showed a period of higher expression of TNFa early that for three patients with humoral allograft rejection, after transplantation, and suggest that its release may not elevated levels coincided with rejection episodes [69] .
be specific to rejection. Expression of TNFa following However, in other studies [69] [70] [71] [72] , there was no associa-ATG (anti-thymocyte globulin) therapy [73, 74] and istion between serum TNFa levels and grade of cellular chaemia [75, 76] , have been well documented. ATG stimurejection. Grant et al. [71] found that when samples were lates cytokine release, including TNFa [73, 74] . Thus taken after the initial 30 days of transplantation, (in order detection of cytokines during this stage may not be a to overcome any stimulating effects of surgery, cardiopulreflection of rejection per se. Conversely, induction of monary bypass, or RATG therapy on TNFa levels [73- TNFa mRNA transcripts can be blocked by immuno-76]), there was no demonstrable relationship between suppressive drugs, such as FK506 and cyclosporin [14] . elevated levels of TNFa and grade of rejection. To assess Long term immunosuppression may therefore dampen whether the in situ expression of TNFa is reflected in the down cytokine release. Our demonstration of the early, but serum, the expression of TNFa in situ (for both mRNA not subsequent release of TNFa following transplantation, and protein) was compared with serum TNFa levels [65] .
may reflect this process. That TNFa expression in smooth muscle could be rejection on the subsequent biopsy occasion. This is true triggered by lipid intake was confirmed by electron microonly for mild grades of rejection (ISHLT grades 1A and scopy [89] . Cultured human smooth muscle cells produce 1B). Larger numbers of samples need to be analysed to TNFa when incubated with low density lipoproteins [88] . substantiate these findings. Our studies further concluded TNFa mRNA is synthesised by smooth muscle cells and that intragraft expression of TNFa is not reflected in the by macrophages [90] . The cytokine was present as a serum, rendering the analysis of such levels unacceptable, margin of lesions in reactive areas, where there was little as an alternative method of TNFa detection. Although the lipid and fibrosis. Smooth muscle cells from plaques studies described in this review, do not establish whether respond to both IL-1 and TNFa by manufacturing GMincreased TNFa expression is the 'cause' or 'effect' of CSF [91] . Cytokines may act in an autocrine fashion rejection, the genetic studies indicate that stimulation of within a plaque, for example TNFa may induce expression the inflammatory response (by alloantigen, ATG, or isof TNFa mRNA during monocyte differentiation [92] . chaemia) will result in large amounts of TNFa being Herrman et al. (1998) studied TNFa gene polymorsecreted by individuals with a genetic predisposition to phisms in relation to coronary artery disease and obesity produce higher levels of TNFa.
[93]. The genotypic frequencies were similar in cases and controls in the high-risk populations in Belfast and France. However, the TNFa -308 A allele was more frequent in
Role of TNFa in coronary artery disease (CAD)
Belfast than in France and carriers of this allele were more frequently obese than non-carriers. Thus polymorphisms A large inflammatory component may exist within the are unlikely to contribute to CAD risk but TNFa -308 atherosclerotic lesion of CAD. The inflammatory response polymorphism may be related to obesity. The TNFa -308 is initiated by the presence of memory T cells specific to allele was associated with a parental history of myocardial oxidised low density lipoprotein. The elaboration of ininfarction in both countries, but the lack of a case-control flammatory cytokines, such as TNFa, is orchestrated by difference suggested this association might be spurious. monocytes transmigrating into the lesions, and differentiating into macrophages. TNFa affects lipid metabolism and 4.1. Coronary angioplasty hyper-triglyceridaemia by decreasing lipoprotein lipase activity in cultured adipocytes. [82] It increases hepatic Circulating TNFa is not released during transient isfatty acid synthesis [83] and is associated with increased chaemia in patients undergoing coronary angioplasty [94] . levels of triglycerides [84] . TNFa probably plays a pivotal
The liberation of TNFa during myocardial infarction role in obesity-related insulin resistance. This is by atprobably reflects an acute phase response to myocardial tenuation of insulin receptor signalling by decreasing both necrosis rather than ischaemia. A study of cardioatherecinsulin-stimulated autophosphorylation and the tyrosine tomy specimens taken at the time of percutaneous transkinase activity of the insulin receptor in cultured luminal coronary angioplasty (PTCA) and subsequent adipocytes [85] . TNFa could contribute to the developrestenosis were examined, The lesions were clinically and ment of atheroma through its direct action on endothelial angiographically similar with equivalent lumina diameter function, stimulation of growth factors and chemoattracbefore and after atherectomy. Restenotic lesions had tants, as well as synthesis and stimulation of adhesion increased expression of TNFa and fibronectin compared molecules. Finally, TNFa increases the risk of CAD by with the primary lesions (P5 ,0.05). There was a trend interfering with the thrombotic process by enhancing for a greater number of T cells and increased expression of procoagulant activity (PAI-1, von Willebrand factor) and IL-1 in restenoic areas. An immune-inflammatory reaction suppressing the antithrombotic protein C pathway in probably contributed to neointimal formation and may endothelial cells [86] (Table 1) .
represent a form of wound healing, possibly secondary to TNFa has been demonstrated in 88% of atherosclerotic mechanical injury [95] . In this study there were no lesions but is absent from normal tissues [87] . TNFa significant differences in the relative amounts of fibrosis or expression increases with the severity of the lesion, cellularity when comparing primary atherectomy tissue suggesting it may play a role in disease evolution [88] .
with restenotic tissues. Arbustini et al. [89] showed by Western blotting and Recent studies on coronary graft arteriopathy suggest immunohistochemistry that TNFa was present in lipid-rich there is a reciprocal co-induction of TNFa and IL-1b. Both cytokines regulate endothelial and smooth muscle fibro- [107] . TNFa and IL-6 levels were significantly higher in nectin synthesis [96] . Neutralisation of TNFa activity in mixed venous than arterial blood shortly after reperfusion rabbits after cardiac transplantation reduces both the [107] . The lungs were thought to consume rather than severity and number of coronary artery lesions. This was release pro-inflammatory cytokines in the early phase of associated with less inflammation and a reduced accumulareperfusion. tion of fibronectin in the vessel wall [97] . Meldrum et al. (1998) studied the levels of myocardial TNFa before and after cardiopulmonary bypass, and 4.2. Cardiopulmonary bypass and coronary artery grafts showed that it induced an increase in myocardial TNFa. They used immunolocalisation techniques to demonstrate A series of papers have studied cytokine levels followthat myocardial TNFa was locally produced, subsequent to ing cardiopulmonary bypass. A study of two groups of bypass, by the myocytes themselves [76] . patients, one with an ejection fraction of less than 0.45 (study group) and those of an ejection fraction of greater than 0.55 (control group) having coronary artery bypass 5. Role of TNFa in heart failure grafting were investigated. The study and control groups did not differ with regard to age, sex, vessel involvement, Elevated circulating levels of TNFa and its soluble number of grafts, cross-clamp time, extracorporeal circulareceptors have been demonstrated in advanced congestive tion time, or duration of ventilation [98] . There were no heart failure (CHF) [4, 42, [108] [109] [110] . TNFa has various complications in the control group. In the study group effects on cardiac function, leading to heart failure (disthere were higher levels of IL-2, TNFa, and a higher cussed in Section 2.4). TNFa may thus have a causative maximum cytokine response to extracorporeal circulation role. Mann [34] has argued that as TNFa is produced for IL-2, soluble IL-2 receptor, IL-6 and TNFa. Preoperafollowing all forms of cardiac injury, it may act as a 'stress tive left ventricular dysfunction is associated with a higher response' gene in the heart. Using whole mammalian degree of proinflammatory cytokine release during elective hearts, TNFa mRNA can be induced within 30 min of a coronary artery bypass grafting. Such a response is associstressful stimulus with endotoxin challenge. TNFa mRNA ated with impaired haemodynamics and a higher incidence levels returned to baseline levels soon after removal of the of perioperative complications. This study examined arteristimulus. TNFa stimulation of cultured cardiac myocytes al and mixed venous samples taken at ten points in time resulted in increased heat shock protein (HSP 72) expres-(24 h before, until 48 h after extracorporeal circulation).
sion, which was completely abolished by a neutralising TNFa release proceeded IL-6 liberation. This investigation antibody against TNFa [111] . Very high concentrations of was carried under normothermic conditions, which could TNFa, within the pathophysiological range, resulted in have contributed to the higher level of cytokine release lower levels of HSP expression [34] . [99] , compared with hypothermia.
Immunoreactivity for NO has been demonstrated in Other published data concerning TNFa release during dilated cardiomyopathy [112] . Tissue was obtained from extracorporeal circulation are conflicting. Other studies patients with end stage CHF undergoing primary orthohave given varying results [100] [101] [102] [103] [104] . Wan et al. [105] topic cardiac transplantation or endomyocardial biopsy. studied pro-inflammatory cytokines such as TNFa, IL-6, Inducible NOS was strongly expressed in myocytes in IL-8 and anti-inflammatory cytokines, such as IL-10, in dilated cardiomyopathy, especially in subendocardial areas, patients undergoing cardiopulmonary bypass. The cytoand may contribute to the low contractility and the kines were measured by arterial, coronary sinus and thromboembolic tendency in these patients. Dilated carpulmonary artery catheters. Levels of TNFa and IL-6 were diomyopathy may have an inflammatory component and significantly higher in coronary sinus than arterial blood this will contribute to the pathogenesis and consequent after aortic declamping. TNFa and IL-6 levels were higher cytokine production and iNOS induction [113] . The inin mixed venous than arterial blood within 1 h of declampcreased levels of iNOS in cardiomyopathy coincided with ing. They confirmed the myocardium was a major source an abundant source of TNFa, not present in ischaemic of TNFa and IL-6 in patients undergoing cardiopulmonary heart disease or normal myocardium. There is no increase bypass. Removal of TNFa and IL-6 by haemofiltration has in concentrations in IL-1a, soluble IL-2 receptor or TNFa beneficial effects on children undergoing cardiopulmonary concentrations in mild to moderate heart failure versus bypass [106] but the data do not exclude significant controls. In myocarditis, dilated cardiomyopathy and hycytokine release from other organs. After cardiopulmonary pertrophic cardiomyopathy, TNFa was increased in up to bypass other organs may have an inadequate blood supply 46% of patients in some groups [114] . TNFa may be and could be an important source of such mediators. The raised in less than 25% of patients with acute myocardial release of endotoxin and complement activation, seen infarction with large infarcts complicated by hypotension during bypass, could trigger cytokine release. The lungs and pulmonary oedema [106] . release TNFa during ischaemia and it is known that during Familial hypertrophic cardiomyopathy has been associcardiopulmonary bypass the lung does suffer damage ated with HLA-DR4 and with other major histocom- induces TNFa production [119] . The suppression of this mechanism for cardiac protection [120] . TNFa is a potent cytokine which acts not just on TNFa cannot be used as a marker of allograft rejection, is necessary to establish any causal relationship. 
